Polycaprolactone-based neurotherapeutic delivery of rasagiline targeting behavioral and biochemical deficits in Parkinson’s disease-Reference-Cited by-同舟云学术

Polycaprolactone-based neurotherapeutic delivery of rasagiline targeting behavioral and biochemical deficits in Parkinson’s disease

Published:2019-03-14 Issue:5 Volume:9 Page:891-905
ISSN:2190-393X
Container-title:Drug Delivery and Translational Research
language:en
Short-container-title:Drug Deliv. and Transl. Res.

Author:

Kanwar N.,Bhandari R.,Kuhad A.,Sinha V. R.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

http://link.springer.com/content/pdf/10.1007/s13346-019-00625-2.pdf

Reference28 articles.

1. DeMaagd G, Philip A. Parkinson’s disease and its management part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. Pharmacol Ther. 2015;40(8):504–10 532.

2. De Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5:525–35.

3. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson’s disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci. 2008;1147:93–104.

4. Logroscino G. The role of early-life environmental risk factors in Parkinson disease: what is the evidence? Environ Health Perspect. 2005;113:1234–8.

5. Spatola M, Wider C. Genetics of Parkinson’s disease: the yield. Parkinsonism Relat Disord. 2014;20:S35–8.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Terpene-augmented novasomal gels for the sustainment of rasagiline mesylate delivery; A new approach for treating Parkinson's disease induced by rotenone in rats;Journal of Drug Delivery Science and Technology;2024-02

2. The Management of Parkinson’s Disease: An Overview of the Current Advancements in Drug Delivery Systems;Pharmaceutics;2023-05-15

3. Investigating the Targeting Power to Brain Tissues of Intranasal Rasagiline Mesylate-Loaded Transferosomal In Situ Gel for Efficient Treatment of Parkinson’s Disease;Pharmaceutics;2023-02-05

4. Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems;Pharmaceutics;2022-12-20

5. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future;Journal of Parkinson's Disease;2021-12-21